Rho V Inhibitors
Rho kinase inhibitors, commonly abbreviated as ROCK inhibitors, are a class of chemical compounds that selectively target the Rho-associated, coiled-coil containing protein kinase (ROCK) enzymes. These enzymes, specifically ROCK1 and ROCK2 isoforms, are pivotal in mediating various cellular processes, including contraction, motility, proliferation, and apoptosis. The inhibitors work by binding to the kinase domain of the ROCK proteins, thus impeding their ability to phosphorylate downstream targets. The Rho/ROCK pathway is intrinsically linked to the actin cytoskeleton dynamics, and as such, ROCK inhibitors have a profound impact on cell shape and motility. By inhibiting ROCK activity, these chemicals reduce the phosphorylation levels of myosin light chain (MLC), which is a key regulator of actin-myosin contraction. This results in the relaxation of the actin cytoskeleton, leading to changes in cell adhesion and motility. The inhibition also affects the assembly of focal adhesions and stress fibers, which are integral components of cellular structure and intracellular signaling.
The specificity of ROCK inhibitors lies in their ability to modulate the actomyosin machinery without affecting the global levels of calcium ions or the activity of other kinases involved in muscle contraction. This selective inhibition allows for precise control over the contractile state of cells, influencing processes such as cellular tension and the formation of cellular protrusions. In addition to altering the cytoskeletal dynamics, ROCK inhibitors also modulate the expression of various genes involved in cell survival and apoptosis, which are mediated through the ROCK pathway. By doing so, they can influence cell proliferation and apoptosis indirectly. The effects of ROCK inhibition on cellular processes are profound and diverse, reflecting the central role of the Rho/ROCK pathway in cellular physiology. While their primary action is on the contractility and motility of cells, these inhibitors also have downstream effects on other signaling pathways that are modulated by the mechanical state of the cell, thus implicating a broad spectrum of cellular functions that are regulated by the physical and mechanical properties of the cellular environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
This small molecule inhibits the signaling pathway of the Rho V protein by targeting its downstream effector, the Serum Response Factor (SRF). The inhibition of SRF prevents the transcription of genes downstream of Rho V signaling, leading to decreased Rho V-mediated cellular changes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A potent inhibitor of ROCK, which is a Rho-associated protein kinase. By inhibiting ROCK, Y-27632 prevents the phosphorylation and activation of downstream targets of Rho V, which is crucial for actin cytoskeleton dynamics and cellular motility. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A selective inhibitor of Cdc42 GTPase, which indirectly influences Rho V activity. By inhibiting Cdc42, ML-141 impacts cross-talk between Rho family GTPases, leading to altered Rho V signaling and function. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
An inhibitor that specifically interferes with the activation of Rac1, another Rho GTPase. By modulating Rac1 activity, NSC23766 indirectly affects Rho V signaling pathways, especially in cell motility and morphology. | ||||||
ITX 3 | 347323-96-0 | sc-295214 sc-295214A | 10 mg 50 mg | $145.00 $615.00 | ||
A small molecule that specifically inhibits Trio, a GEF that activates Rho V. By blocking GEF activity, ITX3 indirectly reduces Rho V activation, influencing cytoskeletal dynamics and cellular adhesion. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
A compound that disrupts the interaction between Cdc42 and its GEFs, thus indirectly affecting Rho V activity due to the complex interplay and balance between Rho family GTPases in signaling and cytoskeletal organization. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
A pan-GTPase inhibitor that, while not specific to Rho V, can indirectly inhibit Rho V by targeting the overall family of GTPases, including Rho V’s regulatory proteins, impacting various cellular processes. | ||||||
CASIN | 425399-05-9 | sc-397016 | 10 mg | $460.00 | 1 | |
CASIN inhibits the activity of Cdc42, which, through the interdependence of Rho family GTPases, can subsequently lead to altered Rho V signaling and reduced Rho V-mediated cellular functions. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Although primarily known as cholesterol-lowering agents, statins also prenylation and thus membrane localization of Rho family proteins, including Rho V. This indirect effect can lead to decreased Rho V activity in cellular signaling pathways. | ||||||